Crossmark

A feasibility study using quantitative and interpretable histological analyses of celiac disease for automated cell type and tissue area classification

Crossref DOI link: https://doi.org/10.1038/s41598-024-79570-1

Published Online: 2024-12-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Griffin, Michael

Gruver, Aaron M.

Shah, Chintan

Wani, Qasim

Fahy, Darren

Khosla, Archit

Kirkup, Christian

Borders, Daniel

Brosnan-Cashman, Jacqueline A.

Fulford, Angie D.

Credille, Kelly M.

Jayson, Christina

Najdawi, Fedaa https://orcid.org/0000-0002-2818-8354
Gottlieb, Klaus
License Information

Text and Data Mining valid from 2024-12-02

Version of Record valid from 2024-12-02
More Information

Article History

Received: 24 June 2024

Accepted: 11 November 2024

First Online: 2 December 2024

Declarations

:

: AMG, ADF, KMC, and KG are employees and shareholders of Eli Lilly and Company. MG, CS, QS, DF, AK, CK, DB, JABC, CJ, and FN are shareholders in and current or former employees of PathAI. QW and FN were employees of PathAI at the time of study.

: This study was conducted as specified in WCG IRB protocol number 1316112.

Document is current

Any future updates will be listed below